The HCPLive Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for C difficile, IBS and IBD, Crohn's disease, and more.
April 22nd 2024
Announced on April 18, the approval is based on the VISIBLE 2 trial and comes less than 7 months after the approval of SC vedolizumab in ulcerative colitis.
Show Me the Data: Bridging Clinical Gaps in Later Lines of Metastatic CRC… It’s Easy as VEGFR1, 2, 3!
April 17, 2024
View More
9th Annual School of Gastrointestinal Oncology® (SOGO®)
View More
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
Rapid Oncology Abstract Review®: Key Updates in Gastrointestinal Cancers from the ASCO Annual Meeting
View More
Medical Crossfire®: Bridging Precision Medicine Techniques and Emerging Treatments in Metastatic Colorectal Cancer
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
Burst CME: Incorporating the Latest Updates in IBS Treatment into Your Practice
View More
Advancing Care in Erosive Esophagitis: Towards a Path of Complete Healing
View More
Oncology Town Hall: Live Report from Barcelona for Advances in the Treatment of GI Cancers
View More
Cancer Summaries and Commentaries™: Clinical Updates in RCC from Chicago
View More
Collaborating Across the Continuum™: The Role of Multidisciplinary Care in the Management of Patients with Exocrine Pancreatic Insufficiency
View More
2024 Miami International Symposium of Gastrointestinal Oncology (ISGIO)
October 11-12, 2024
Register Now!
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Community Practice Connections™: 20th Annual Meeting of the International Society of Gastrointestinal Oncology®
View More
Working Group: Streamlining the Pathway from Diagnosis to Treatment in Inflammatory Bowel Disease
View More
Advances In™: The Evolving Role of VEGFR in the Treatment of Refractory mCRC
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Show Me the Data: Bridging Clinical Gaps in Later Lines of Metastatic CRC… It’s Easy as VEGFR1, 2, 3!
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
Tissue Stewardship and the Evolving Role of Genomic Alterations in Providing Precision NSCLC Care
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Delphi Consensus Outlines Anti-TNF Introduction, Monitoring Guidelines for Patients with IBD
October 24th 2023Experts recommended the early use of anti-TNF therapy for patients with ulcerative colitis and Crohn disease, offering further input regarding the introduction, optimization, and maintenance of the treatment for patients with IBD.
Study Finds Infliximab Biosimilar Switch Is Safe, Effective for Patients with IBD
October 24th 2023Switching from biosimilar CT-P13 to SB2 is safe and effective, according to new research. The patients in the study had no significant changes in their psychometric assessments during the 12 month follow up.
MACE, VTE Risk Not Increased by Advanced Therapies for Inflammatory Bowel Disease
Advanced therapies for inflammatory bowel disease, namely small molecules and biologic therapies, did not increase the risk of a major adverse cardiovascular event or venous thromboembolism.
Diet and Food Access Are Risk Factors for Early Onset Colorectal Cancer Mortality
Consumption of fruit and vegetables was found to be protective while consuming sweet snacks and candy along with supercenters and warehouse clubs as a primary food source were determined to be risk factors for early onset colorectal cancer mortality.
FDA Approves First Subcutaneous Infliximab for Maintenance Therapy in UC and Crohn Disease
October 23rd 2023The approval of infliximab-dyyb as a maintenance therapy following IV infliximab for patients with moderately to severely active ulcerative colitis and Crohn disease was announced on October 22, 2023.
Next-Generation Cologuard Improves Colorectal Cancer Detection, False Positive Rates in BLUE-C
October 23rd 2023Thomas F. Imperiale, MD, discusses the pivotal findings showing improvements to the prior iteration of Cologuard, as well as bettered sensitivity and specificty relative to fecal immunochemical tests.